Notes on AVNR:
Avanir Pharmaceuticals, Inc. (Avanir) is a pharmaceutical company focused on acquiring, developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company's lead product candidate, Zenvia (dextromethorphan hydrobromide/quinidine sulfate), has completed three Phase III clinical trials for the treatment of pseudobulbar affect (PBA) and has completed a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain (DPN pain). In addition to its focus on products for the central nervous system, Avanir also has a number of partnered programs in other therapeutic areas. Its product, docosanol 10% cream, (sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA)
News: Avanir Pharmaceuticals Welcomes Analyst Initiation; AVNR, PCYC, PTIE
http://www.learningmarkets.com/News-Feed/2010070127512/avanir-pharmaceuticals-welcomes-analyst-initiation-avnr-pcyc-ptie.html
BarChart.com - Recommends this as a Buy!
No comments:
Post a Comment